Connecting Innovation to Purpose

23 CRB-701-01 Study Design (Corbus) Dose escalation (IND open: FPI Expected Q1 2024) 1.8 mg/kg 2.7 mg/kg 3.6 mg/Kg 4.5 mg/Kg Project Optimus [dose optimization) Randomized to 2 doses of CRB-701 monotherapy Randomized to 2 doses of CRB-701+CPI Dose expansion at RP2D Bladder cancer niche population[s] Non-UC tumors: A B C Basket of nectin-4 positive tumors

View entire presentation